Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Administration, Cutaneous
Adult
Aged
Betamethasone
/ analogs & derivatives
Calcitriol
/ analogs & derivatives
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Combinations
Dyssomnias
/ etiology
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Pruritus
/ drug therapy
Psoriasis
/ complications
Quality of Life
Randomized Controlled Trials as Topic
Single-Blind Method
Visual Analog Scale
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
23
07
2018
accepted:
24
10
2018
pubmed:
7
12
2018
medline:
6
8
2019
entrez:
7
12
2018
Statut:
ppublish
Résumé
Itch is common in psoriasis, adversely affecting health-related quality of life (HRQoL) and sleep. We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL vs. foam vehicle. We pooled data from three Phase II/III trials (NCT01536886/NCT01866163/NCT02132936) of Cal/BD foam vs. foam vehicle in adults with mild-severe psoriasis. For itch-related analyses, patients with baseline itch visual analogue scale (VAS) >40 (range 0-100) were analysed. Outcomes included the following: itch VAS reduction >40, ≥70% improvement in itch (Itch70) or itch-related sleep loss, 75% improvement in modified Psoriasis Area and Severity Index (excluding head; mPASI75) and Dermatology Life Quality Index (DLQI) scores 0/1 through 4 weeks. Of 837 patients, 800 had baseline itch VAS >0 (Cal/BD foam, n = 610; foam vehicle, n = 190); 484 had baseline itch VAS >40. There was no correlation between itch VAS score and mPASI at baseline (R Compared with foam vehicle, Cal/BD foam offers more rapid and effective itch relief, with associated significant improvements in sleep and DLQI.
Sections du résumé
BACKGROUND
BACKGROUND
Itch is common in psoriasis, adversely affecting health-related quality of life (HRQoL) and sleep.
OBJECTIVE
OBJECTIVE
We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL vs. foam vehicle.
METHODS
METHODS
We pooled data from three Phase II/III trials (NCT01536886/NCT01866163/NCT02132936) of Cal/BD foam vs. foam vehicle in adults with mild-severe psoriasis. For itch-related analyses, patients with baseline itch visual analogue scale (VAS) >40 (range 0-100) were analysed. Outcomes included the following: itch VAS reduction >40, ≥70% improvement in itch (Itch70) or itch-related sleep loss, 75% improvement in modified Psoriasis Area and Severity Index (excluding head; mPASI75) and Dermatology Life Quality Index (DLQI) scores 0/1 through 4 weeks.
RESULTS
RESULTS
Of 837 patients, 800 had baseline itch VAS >0 (Cal/BD foam, n = 610; foam vehicle, n = 190); 484 had baseline itch VAS >40. There was no correlation between itch VAS score and mPASI at baseline (R
CONCLUSION
CONCLUSIONS
Compared with foam vehicle, Cal/BD foam offers more rapid and effective itch relief, with associated significant improvements in sleep and DLQI.
Substances chimiques
Drug Combinations
0
calcipotriene
143NQ3779B
betamethasone-17,21-dipropionate
826Y60901U
Betamethasone
9842X06Q6M
Calcitriol
FXC9231JVH
Types de publication
Journal Article
Langues
eng
Pagination
709-717Subventions
Organisme : LEO Pharma A/S
Informations de copyright
© 2018 European Academy of Dermatology and Venereology.